Immunofluorescence stainings for the CD10 antigen and terminal deoxynucleotidyl transferase (TdT) can be used for the detection of leukemic blasts in CD10
Introduction
About 85% of acute lymphoblastic leukemias (ALL) in childhood concern CD10
+ precursor-B-ALL. 1,2 Current treatment protocols induce complete remission in nearly all ALL patients, but still 25 to 30% relapse, implying that the treatment did not kill all clonogenic leukemic cells. To evaluate the effectiveness of a treatment, bone marrow (BM) samples during and after treatment can be closely monitored for the presence of remaining ALL cells (ie minimal residual disease; MRD) by the use of immunophenotyping. [4] [5] [6] [7] However, most ALL cells have immunophenotypes comparable to normal immature lymphoid cells. [4] [5] [6] [7] [8] Therefore, the use of immunological markers such as CD10 and terminal deoxynucleotidyl transferase (TdT) for the detection of CD10
+ precursor-B-ALL cells is hampered by the expression of CD10 and TdT in normal B-cell precursors. [4] [5] [6] [7] [8] [9] The frequencies of TdT + and CD10 + cells are known to be age dependent 4, 10, 11 and the numbers of positive cells can increase substantially after cessation of maintenance therapy in ALL patients, 4, 10, 12, 13 as well as after allogeneic and autologous BM transplantation. 14, 15 Although CD10/TdT double immunofluorescence stainings generally allow discrimination between normal heterogeneous precursor-B-cell populations and homogeneous CD10 + /TdT + leukemic cells in BM, 4, 9, 16, 17 a (massive) regeneration of normal precursor-B-cells can possibly hinder this discrimination, leading to an incorrect interpretation of immunophenotyping results. In order to recognize aberrant patterns in time, the normal patterns of regenerating precursor-B-cells during and after therapy need to be well known. We monitored precursor-B-ALL patients during the last 15 years using TdT/CD10 and TdT/CD10/CD19 double and triple stainings. 4, 5 This included 46 children, who were treated according to three different treatment protocols and were in continuous complete remission (CCR) . In this report we focused on the regeneration processes of CD10 + /TdT + and CD10 + /TdT − precursor-B-cells in BM during therapy and after cessation of therapy, and we investigated the effect of different treatment protocols on the regeneration pattern of the precursor-B-cell compartment.
Materials and methods

Patients
The 46 children in this study were all in CCR and were treated according to protocols of the Dutch Childhood Leukemia Study Group (DCLSG). Three different treatment protocols were used related to the date of diagnosis: DCLSG protocol VI (intake: December 1984-July 1988), protocol VII (intake: July 1988-October 1991), or protocol VIII (intake: October 1991-January 1997).
In protocol VI only children with non-high-risk characteristics were treated, ie white blood cell count (WBC) Ͻ50 × 10 9 /l, no mediastinal enlargement, and no initial central nervous system (CNS) leukemia; they comprised about 70% of all children with ALL. 18 Children with high-risk characteristics diagnosed in this period were treated according to local protocols. Protocols VII and VIII were BFM-like proto-cols with classification of patients into standard-, medium-, and high-risk groups. 19, 20 Hereto a risk factor (RF) was calculated according to the following formula: RF = 0.2 log (BL + 1) + 0.06 LI + 0.04 SP in which: BL = number of blasts/mm 3 in blood at diagnosis; LI and SP = enlargement of the liver and the spleen, respectively, in cm under the costal margin in medioclavicular line. Children were classified as standardrisk group (SRG) in case of RF Ͻ0.8 and not having initial CNS leukemia, pre-T-ALL or T-ALL, mediastinal enlargement or characteristics of high-risk patients. The medium-risk group (MRG) was classified as having a RF Ͼ0.8 and/or having an initial CNS leukemia, pre-T-ALL or T-ALL, or mediastinal enlargement. The high-risk group (HRG) patients were either diagnosed as acute undifferentiated leukemia, or had a WBC Ͼ1 × 10 9 /l at day 8 of the treatment, or were late-or nonresponders to induction treatment, or were diagnosed with t(4;11) or t(9;22).
Only SRG and MRG patients in CCR were evaluated in this study. BM samples were taken at regular time points during treatment and up to 3 years after treatment. Eight patients from the ALL-VI protocol were evaluated; four of them were followed for a long time period after stopping therapy. The patient groups of the ALL-VII and ALL-VIII protocols concerned 10 patients (all MRG) and 28 patients (14 SRG and 14 MRG), respectively. BM samples of most patients were analyzed immunophenotypically up to 3 years after the end of treatment.
Treatment protocols
The medication and the clinical results of the ALL-VI protocol were recently published. 18 In short, the induction treatment in the ALL-VI protocol consisted of vincristine (VCR), dexamethasone (DEXA), and l-asparaginase (L-ASP). After complete remission was achieved, three weekly courses of 24-h intravenous infusions with methotrexate (MTX) in combination with intrathecal MTX and prednisone (PRED) were administered. Maintenance treatment consisted of cycles of 5 weeks daily 6-mercaptopurin (6-MP) orally and weekly MTX alternating with 2 weeks of DEXA and two weekly injections of VCR for 2 years. Protocol VI for non-HRG ALL patients differed most from the preceding protocols in CNS prophylaxis. Because of the high number of CNS relapses and the unwanted late side-effects, 20 cranial irradiation was omitted and replaced by the aforementioned three courses of highdose MTX, followed by intrathecal triple therapy with MTX, PRED and cytarabine (ARA-C) every 7 weeks during the first year of maintenance treatment.
Protocols VII and VIII were based on the ALL-BFM 86 and ALL-BFM 90 trials, respectively with minor modifications. 19, 20 Induction treatment in both protocols consisted of VCR, PRED, daunorubicin (DNR), L-ASP, cyclophosphamide (CP), ARA-C and 6-MP. The latter three (administered in phase 2 of the induction treatment) were not prescribed for SRG patients in protocol VIII. In protocol VIII for SRG patients the treatment was directly continued with CNS directed treatment without a pause. In protocol VII and VIII for MRG patients, the treatment was continued after a stop in therapy of 2 weeks. The CNS directed treatment consisted of daily 6-MP orally for 8 weeks and four 24-h infusions with MTX and intrathecal injections with either MTX (protocol VII) or triple therapy (protocol VIII) every 2 weeks. MRG patients in protocol VIII were randomized to receive daily 6-MP orally or high doses of 6-MP intravenously every 2 weeks after the 24-h MTX infusions.
Leukemia
This treatment was followed, after a 2-week stop, by a reinduction treatment, which consisted of DEXA, VCR, adriamycin (ADR), L-ASP, CP, ARA-C, 6-thioguanin (6-TG) and intrathecal MTX (protocol VII) or intrathecal triple therapy (protocol VIII). After another stop of 2 weeks, therapy was continued with maintenance treatment, consisting of 6-MP daily orally and MTX weekly orally. SRG patients in protocol VIII were randomized to receive or not 20 high-dose L-ASP weekly intramuscularly. The total duration of protocol VII and protocol VIII was 78 weeks and 105 weeks, respectively.
Cell samples
A total of 634 BM samples were collected from the 46 ALL patients at regular time points after induction treatment and before each subsequent treatment block and once every 3 months during and after maintenance treatment up to 3 years post-therapy. BM mononuclear cells (MNC) were isolated by Ficoll-Paque (density 1.077 g/cm 3 ; Pharmacia, Uppsala, Sweden). Cells were washed with phosphate-buffered saline (PBS) and resuspended in PBS containing 1% bovine serum albumin (BSA) at a concentration of 10 × 10 6 cells/ml. In order to analyze and compare BM samples within one patient group, the individual BM sampling time points were synchronized according to the sampling time points of the treatment protocols.
Immunofluorescence staining, immunofluorescence microscopy, and flow cytometry
Two techniques were used for the analysis of the CD10 surface membrane antigen in combination with the staining for nuclear TdT: fluorescence microscopy (1984-1994) and flow cytometry (1989-now).
For fluorescence microscopic analysis MNC were stained (10 min at room temperature; RT) for the CD10 antigen (OKB-CALLA; Ortho Diagnostic Systems, Raritan, NJ, USA) followed by tetramethyl rhodamine isothiocyanate (TRITC)-conjugated goat-anti-mouse IgG (Central Laboratory Blood Transfusion Service, Amsterdam, The Netherlands; 10 min RT). Subsequently, cytocentrifuge preparations (generally containing 25 000-50 000 MNC) were fixed in methanol (4%; 30 min RT), washed with PBS (15 min RT), and stained with polyclonal rabbit anti-TdT antiserum (Supertechs, Bethesda, MD, USA) for 30 min at RT, followed by staining with fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (Supertechs) for 30 min at RT. 4, 19 The cytocentrifuge preparations were analyzed on fluorescence microscopes with phase contrast facilities (Zeiss, Oberkochen, Germany). For flow cytometric CD10/TdT analysis, 5 × 10 5 MNC were stained (10 min RT) with phycoerythrin (PE)-conjugated CD10 (J5-PE; Coulter/Immunotech, Westbrook, ME, USA). Samples were washed and subsequently permeabilized and fixed with FACS Brand Lysing Solution (Becton Dickinson Immunocyto-metry Systems, San Jose, USA; 10 min RT) after which the MNC were stained with FITC-conjugated anti-TdT (hTdT-6; Supertechs). 22 
Comparison of fluorescence microscopic and flow cytometric analysis of precursor-B-cells
For a period of 8 months fluorescence microscopy and flow cytometry were used in parallel for comparing the results of the CD10 and TdT stainings. More than 450 BM samples of precursor-B-ALL patients and healthy controls were analyzed with both techniques for the percentages of TdT + cells. 22, 23 In addition the percentages of CD10 + /TdT + cells were analyzed in a total of 53 BM samples using both techniques in parallel.
Results
Comparison between microscopic and flow cytometric detection of precursor-B-cell populations
In our earlier studies, 450 BM samples were analyzed in parallel to compare microscopic and flow cytometric detection of the TdT antigen. 22, 23 The results of both methods correlated very well (P Ͻ 0.00001) and for the 275 BM samples with Ͼ1% TdT + cells the percentages of TdT + cells as found with both techniques showed an excellent correlation: r = 0.978. Additionally, 53 BM samples were analyzed in parallel with both techniques for the CD10/TdT double staining, resulting in an excellent correlation (r = 0.9498) between the percentages of CD10 + /TdT + cells (Figure 1 ). 
Precursor-B-cells in BM during and after treatment
The 46 patients included in this study were diagnosed with 80-95% precursor-B-ALL cells at the start of therapy ( Figure  2a ). Induction treatment resulted in a morphologically defined state of complete remission with CD10 + and CD10 + /TdT + frequencies generally below 1% of total BM (Figure 2b ). All patients remained in CCR. It should be noted that the frequencies of CD10 + cells in this manuscript comprise both CD10 + /TdT + and CD10 + /TdT − precursor-B-cells. Percentages are expressed as mean ± s.e.m.
Precursor-B-cells in BM during and after protocol VI:
Just before start of maintenance treatment the percentages of CD10 + cells and CD10 + /TdT + cells slightly increased from a mean of 0.3 ± 0.1% and 0.04 ± 0.03% during induction therapy to a mean of 0.8 ± 0.5% and 0.13 ± 0.07%, respectively, and stayed at this level during maintenance treatment ( Figure  3a ). BM samples of four patients were analyzed over a longer period. A similar pattern of precursor-B-cell frequencies was found in each patient. A significant increase of precursor-Bcells, especially in the percentage of CD10 + cells, was observed shortly after stopping the therapy. The percentages of CD10
+ cells increased 20-fold to a mean of 23.0 ± 7.8% and stayed at those levels for up to 3 years after stopping therapy. Only after this time period a slight decrease in the percentage of CD10 + cells could be observed (the last time point in the follow-up). The CD10 +
/TdT
+ cells increased four-fold to about 4.5 ± 1.2% and, comparably to the increased frequencies of CD10 + cells, stayed at those levels for up to 3 years after stopping therapy.
Precursor-B-cells in BM during and after protocol VII:
After the first treatment pause after attainment of complete remission, a 10-fold increase in precursor-B-cell frequencies was observed (Figure 3b ). The percentages of CD10 + cells and CD10
+
/TdT
+ cells increased from a mean of 3.3 ± 1.2% and 1.9 ± 0.9% at the end of induction therapy up to 28.3 ± 6.2% and 10.5 ± 2.3%, respectively, at the point of starting the CNS directed protocol, and 21.1 ± 5.5% and 6.1 ± 1.4% 2 weeks after the CNS directed treatment just before re-induction therapy. During maintenance treatment, the percentages of CD10 
+ cells increased almost 10-fold to a mean of 4.3 ± 0.7% and also stayed at this high level for at least 2 years.
Precursor-B-cells in BM during and after protocol VIII:
The dynamics of the precursor-B-cell frequencies during and after treatment with protocol VIII (SRG and MRG: Figure 3c and d, respectively), are comparable to protocol VII. After reaching the state of complete remission, CD10
+ and CD10 + /TdT + cells in the SRG patients increased from a mean of 1.4 ± 0.9% and 0.08 ± 0.07%, respectively, at the end of induction therapy up to mean levels of 14.6 ± 3.9% and 6.6 ± 1.5%, respectively, 2 weeks after CNS directed treatment, just before starting re- 
Figure 2
Representative examples of CD10/TdT double stainings on BM-MNC at primary diagnosis (a), at remission (b), during regeneration after a 2-week therapy stop following induction treatment (c) during regeneration after a 2-week stop following CNS directed treatment (d), and during regeneration after cessation of treatment (e). Cell populations were analyzed within a life gate on lymphocytes, as was defined by the light scatter characteristics. induction therapy. Two weeks after re-induction therapy, ie at the point of starting maintenance therapy, BM samples displayed comparably high numbers of precursor-B-cells. During maintenance therapy mean levels of 0.8 ± 0.3% and 0.5 ± 0.1% were observed for CD10 + and CD10 + /TdT + cells, respectively, which increased to 38.8 ± 2.5% for CD10 + cells and 4.5 ± 0.4% for CD10
+
/TdT
+ cells after cessation of therapy.
In the BM of MRG patients CD10 + and CD10 + /TdT + cells increased from a mean of 1.6 ± 0.7% and 0.05 ± 0.02%, respectively, at the end of induction therapy to mean levels of 15.4 ± 2.9% and 10.5 ± 1.7% just before starting CNSdirected therapy. Precursor-B-cell levels were comparably high at the point of initiating re-induction and maintenance therapy. During maintenance therapy, mean levels of 0.8 ± 0.2% and 0.6 ± 0.2% were measured for CD10 + and CD10 + /TdT + cells, respectively, increasing to 38.6 ± 3.8% and 4.7 ± 0.7% respectively after cessation of therapy. Frequencies stayed this high for up to 2 years after stopping treatment.
Precursor-B-cell populations at different moments of BM regeneration
Two populations of precursor-B-cells were discriminated during BM regeneration: the 'immature' CD10 
Discussion
To evaluate the effectiveness of treatment, BM samples can be monitored for the occurrence of minimal disease by use of immunophenotyping. [4] [5] [6] [7] For correct interpretation of the immunophenotyping results in precursor-B-ALL patients, information is needed about the regeneration of normal precursor-B-cell populations in BM during and after treatment. Earlier studies showed that the use of separate CD10 and TdT stainings are not suited for predicting relapse in CD10
+ precursor-B-ALL, since a threshold level for impending relapse could not easily be defined. 4, 24 Therefore it was emphasized that double immunofluorescence stainings for CD10 and TdT are needed to discriminate between the occurrence of leukemic blasts and regenerating bone marrow. 1, 4, 5, 9 In the present study, we investigated the kinetics of the 'immature' CD10 + /TdT + and 'more mature' CD10 + /TdT − precursor-B-cell populations in 634 BM samples from 46 CCR patients during and after treatment according to three different treatment protocols of the DCLSG. We observed a prolonged expansion of precursor-B-cell frequencies after cessation of chemotherapy, irrespective of the treatment protocol. The frequencies per MNC observed after cessation of maintenance treatment could be as high as 30% for total CD10
+ cells and Figure 3 for precise time schedule. b Post-maintenance data are from the first BM sample taken after cessation of therapy.
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5% for CD10
+ /TdT + cells and were significantly elevated when compared to precursor-B-cell populations in normal BM samples. In normal BM samples of different ages (n = 6), which were studied in the context of the BIOMED-1 Concerted Action 'Investigation of minimal residual disease in acute leukemia: International standardisation and clinical evaluation', 11, 25 we found that mean CD10 + and CD10 + /TdT + frequencies per MNC were as low as 1.07 ± 0.32% and 0.19 ± 0.05% respectively (Figure 3; Ref. 11 ). Long-term follow-up of patients from protocol VI and protocol VII revealed that precursor-B-cell levels remained elevated for even more than 3 years post-treatment. It has not been established yet for how long these increased levels persist in BM. In case of autologous BM transplantation, precursor-B-cell frequencies are significantly elevated up to 1 year after transplantation but decrease subsequently. (Table 1) . Since the first post-treatment BM samples were taken about 6 weeks after cessation of therapy, we can only speculate about the kinetics of the post-treatment BM regeneration. Six weeks post-treatment was apparently sufficient to reach maximum levels in precursor-B-cell populations, which did not differ significantly between the three treatment protocols ( Figure 3) .
In addition to the post-treatment regeneration, elevated levels of precursor-B-cells were also observed during treatment in protocols VII and VIII, but not in protocol VI. This precursor-Bcell regeneration during protocols VII and VIII appeared to be related to the therapy stops. The MRG patients in protocols VII and VIII had a 2-week treatment stop after induction treatment, after CNS directed treatment, and after re-induction treatment. The SRG patients in protocol VIII had a 2-week treatment stop after the CNS directed treatment and after the re-induction treatment, but not after the first induction treatment. Due to the fact that BM samples were taken only at the start of each therapy block (Figure 3) , a therapy-induced decline in precursor-B-cell numbers and a subsequent rise during the treatment stop could not be recorded.
The precursor-B-cell regeneration after the 2-week stops during treatment clearly differed from the post-treatment regeneration. The 'more mature' CD10 + /TdT − precursor-Bcells frequencies were five-fold lower (1.6-12.7) than the frequencies found after cessation of therapy, while the 'immature' CD10 + /TdT + frequencies were two-fold (1.6-2.2) higher, resulting in lower ratios of 'more mature' (CD10 (Table 1) . Furthermore, the precursor-B-cell regeneration post-induction or post-re-induction in protocol VIII showed lower frequencies of the 'more mature' CD10 
/TdT
− cells, but it seems more likely that the intensity of the preceding treatment block influences the type of subsequent precursor-B-cell regeneration. Evidently, 2 week therapy stops after the less intensive CNS-directed treatLeukemia ment resulted in precursor-B-cell regeneration with higher 'mature/immature' ratios (1.2-2.8) than the 2 week therapy stops after the high-intensity induction or reinduction treatment in protocol VIII ('mature/immature' ratios of 0.4-0.8). Apparently the low intensity maintenance treatment, the moderate intensity CNS directed treatment, and the high intensity induction/re-induction treatment resulted in high, moderate, and low 'mature/immature' ratios, respectively, implying that the pattern of precursor-B-cell regeneration is related to the type of preceding treatment.
Dworzak et al 26 studied the precursor-B-cell compartment in a small series of normal and post-chemotherapy pediatric BM samples (n = 23) with several surface markers, such as CD10, CD19, CD20 and CD34. Although they did not include TdT as a specific marker for immature precursor-B-cells, they could define three major subsets of precursor-B-cells. They also found higher frequencies of immature subsets in postinduction BM samples as compared to post-maintenance BM samples, whereas in normal BM samples the most immature subset was relatively small. 26 The information from our study has important implications for the interpretation of immunophenotyping results during treatment, eg for BM samples taken at unusual time points during treatment or taken during infection periods, when treatment is temporarily stopped. Especially at these time points it is crucial to know what type of CD10 and TdT expression patterns can be expected and how to discriminate relapse from precursor-B-cell regeneration. This was illustrated by a BM sample of an acute myeloid leukemia patient during therapy, which was cytomorphologically diagnosed as containing a lymphoblastic malignancy. Immunofluorescence staining for CD10 and TdT however, clearly displayed the characteristic heterogeneous staining pattern of precursor-B-cell regeneration (Figure 4a ). This was confirmed by Southern blotting and heteroduplex PCR analysis of total BM DNA, which displayed polyclonal immunoglobulin heavy chain (IGH) gene rearrangements (Figure 4b and c) thereby confirming the immunophenotyping data. [27] [28] [29] Another patient was immunophenotypically suspected for a common-ALL about half a year before the cytomorphological ALL diagnosis. Double immunofluorescence staining for CD10 and TdT showed a homo- 
− precursor-B-cells (Figure 5a ). In this case Southern blotting of total BM DNA displayed a monoclonal IGH gene rearrangement, thereby confirming the immunophenotyping results (Figure 5b) . [27] [28] [29] The latter finding is in concert with the data from Knulst et al 9 and Morley et al 30 who demonstrated the presence of smoldering precursor-B-ALL in BM by means of immunophenotyping and immunogenotyping, respectively, before it could be detected by cytomorphology. Our study shows that regeneration of the precursor-B-cell compartment in BM can be observed during and after cytotoxic treatment protocols and that the pattern of regeneration seems to be dependent on the intensity of the preceding treatment. Knowledge concerning these patterns is essential for correct interpretation of immunophenotyping data obtained during follow-up of acute leukemia patients. [4] [5] [6] [7] Particularly in precursor-B-ALL patients, regeneration of normal precursor-Bcells should not be mistaken for a relapse. In this long-term follow-up study over a period of 15 years the immunophenotyping was limited to CD10/TdT double stainings, but in the mean time several triple labelings have been developed and evaluated in the collaborative studies of the BIOMED-1 Concerted Action. 11, 25 In particular the TdT/CD10/CD19 and CD10/CD20/CD19 triple labelings appeared to be useful for evaluation of the normal precursor-B-cell compartment, as well as for monitoring of minimal disease in precursor-B-ALL patients. 
